Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following HearingSeptember 10, 2019

Company Committed to Listing on Major Exchange

Emmaus Life Sciences Granted European Patent for use of Pharmaceutical-grade L-glutamine in Treating DiverticulosisSeptember 03, 2019

Related patents granted in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia; Patents pending in Brazil and other countries

Emmaus Life Sciences Adds Oncology Supply as DistributorAugust 28, 2019

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today the addition of Oncology Supply, a part of Amerisource Bergen, as a distributor of its signature product, Endari® (L-glutamine oral powder).

Emmaus Life Sciences to Host "Sideline Sickle Cell" Community Town Hall with ASAP and FSCDR in South FloridaAugust 14, 2019

Campaign spokesperson Solomon Wilcots will be joined by fellow NFL Veteran Antonio "Dayla" Brown, the Advancing Sickle Cell Advocacy Project (ASAP) and the Foundation for Sickle Cell Disease Research (FSCDR)

Emmaus Life Sciences Reports Sharply Improved 2019 Second Quarter Financial ResultsAugust 12, 2019

Net Revenues Increase 128% Year-Over-Year, as FDA-Approved Treatment for Sickle Cell Disease Rolls Out